EP2844756A4 - MODULATION OF IMMUNE RESPONSES - Google Patents

MODULATION OF IMMUNE RESPONSES

Info

Publication number: EP2844756A4
Authority: EP; European Patent Office
Prior art keywords: modulation; immune responses; immune; responses
Prior art date: 2012-04-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

EP13784572.3A

Other languages

German (de)

French (fr)

Other versions

EP2844756A1 (en

Inventor

Glen N Barber

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-30

Filing date

2013-04-30

Publication date

2016-02-24

2012-04-30 Priority claimed from US13/460,408 external-priority patent/US20130039933A1/en

2013-04-30 Application filed by Individual filed Critical Individual

2015-03-11 Publication of EP2844756A1 publication Critical patent/EP2844756A1/en

2016-02-24 Publication of EP2844756A4 publication Critical patent/EP2844756A4/en

Status Ceased legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Biophysics (AREA)
Oncology (AREA)
Physics & Mathematics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP13784572.3A 2012-04-30 2013-04-30 MODULATION OF IMMUNE RESPONSES Ceased EP2844756A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13/460,408 US20130039933A1 (en)	2008-08-04	2012-04-30	Sting (stimulator of interferon genes), a regulator of innate immune responses
PCT/US2013/038840 WO2013166000A1 (en)	2012-04-30	2013-04-30	Modulating immune responses

Publications (2)

Publication Number	Publication Date
EP2844756A1 EP2844756A1 (en)	2015-03-11
EP2844756A4 true EP2844756A4 (en)	2016-02-24

Family

ID=49514802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP13784572.3A Ceased EP2844756A4 (en)	2012-04-30	2013-04-30	MODULATION OF IMMUNE RESPONSES

Country Status (7)

Country	Link
EP (1)	EP2844756A4 (en)
JP (1)	JP2015516989A (en)
KR (1)	KR20150004416A (en)
CN (1)	CN104540945A (en)
AU (1)	AU2013256468A1 (en)
CA (1)	CA2907616A1 (en)
WO (1)	WO2013166000A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2858722B8 (en)	2012-06-08	2018-02-21	Aduro BioTech, Inc.	Compostions and methods for cancer immunotherapy
WO2014093936A1 (en)	2012-12-13	2014-06-19	Aduro Biotech, Inc.	Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
MX380908B (en)	2012-12-19	2025-03-12	Univ Texas	Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
CU24376B1 (en)	2013-04-29	2018-12-05	Memorial Sloan Kettering Cancer Center	ANALOGS OF THE CYCLIC GMP-AMP (cGAMP) ASSETS AS MODULATORS OF THE SYNTHETIC CYCLIC GMP-AMP (cGAS) AND PHARMACEUTICAL COMPOSITIONS OF THE SAME
US20140329889A1 (en)	2013-05-03	2014-11-06	The Regents Of The University Of California	Cyclic di-nucleotide induction of type i interferon
HRP20191972T1 (en)	2013-05-18	2020-02-07	Aduro Biotech, Inc.	Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US9549944B2 (en)	2013-05-18	2017-01-24	Aduro Biotech, Inc.	Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2015017652A1 (en)	2013-07-31	2015-02-05	Memorial Sloan-Kettering Cancer Center	Sting crystals and modulators
CA2950033A1 (en)	2014-06-04	2015-12-10	Glaxosmithkline Intellectual Property Development Limited	Cyclic di-nucleotides as modulators of sting
GB201501462D0 (en)	2015-01-29	2015-03-18	Glaxosmithkline Ip Dev Ltd	Novel compounds
MX2017011597A (en)	2015-03-10	2018-05-11	Aduro Biotech Inc	Compositions and methods for activating "stimulator of interferon gene" -dependent signalling.
AU2016362697B2 (en)	2015-12-03	2018-07-12	Glaxosmithkline Intellectual Property Development Limited	Cyclic purine dinucleotides as modulators of STING
CN106540260A (en) *	2015-12-09	2017-03-29	聊城市奥润生物医药科技有限公司	Interferon gene stimulatory protein(SP)（STING）Application of the agonist in anti-alzheimer's disease
CA3017524A1 (en)	2016-03-18	2017-09-21	Immune Sensor, Llc	Cyclic di-nucleotide compounds and methods of use
CN106539757A (en) *	2016-03-20	2017-03-29	聊城市奥润生物医药科技有限公司	Application of the ring dinucleotide cGAMP- liposomees in antitumor
EA201892128A1 (en)	2016-04-07	2019-04-30	Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	HETEROCYCLIC AMIDES USEFUL AS MODULATORS
JP6746712B2 (en)	2016-04-07	2020-08-26	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	Heterocyclic amides useful as protein regulators
WO2018009466A1 (en)	2016-07-05	2018-01-11	Aduro Biotech, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US20190351039A1 (en)	2017-02-01	2019-11-21	Modernatx, Inc.	Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CN106667914B (en) *	2017-03-13	2022-02-01	杭州星鳌生物科技有限公司	Composition of targeted liposome-cyclic dinucleotide, preparation method and application of targeted liposome-cyclic dinucleotide in resisting tumors
EP3692034A1 (en)	2017-10-05	2020-08-12	GlaxoSmithKline Intellectual Property Development Limited	Modulators of stimulator of interferon genes (sting)
JP7262451B2 (en)	2017-10-05	2023-04-21	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	Administration method of STING agonist
WO2019069269A1 (en)	2017-10-05	2019-04-11	Glaxosmithkline Intellectual Property Development Limited	Modulators of stimulator of interferon genes (sting) useful in treating hiv
GB201807924D0 (en)	2018-05-16	2018-06-27	Ctxt Pty Ltd	Compounds
WO2020006432A1 (en)	2018-06-28	2020-01-02	Eternity Bioscience Inc.	Fused tricyclic heterocycle compounds and therapeutic uses thereof
TW202104214A (en)	2019-04-05	2021-02-01	英商葛蘭素史密斯克藍智慧財產發展有限公司	Chemical compounds
GB201910304D0 (en)	2019-07-18	2019-09-04	Ctxt Pty Ltd	Compounds
GB201910305D0 (en)	2019-07-18	2019-09-04	Ctxt Pty Ltd	Compounds
EP4075980B1 (en)	2019-12-18	2025-07-23	Stinginn LLC	Substituted 1,2, 4-triazoles and methods of use
WO2021119753A1 (en)	2019-12-18	2021-06-24	Ctxt Pty Limited	Compounds
US11897888B1 (en)	2020-04-30	2024-02-13	Stinginn Llc	Small molecular inhibitors of sting signaling compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110262485A1 (en) *	2008-08-04	2011-10-27	University Of Miami	Sting (stimulator of interferon genes), a regulator of innate immune responses

2013
- 2013-04-30 AU AU2013256468A patent/AU2013256468A1/en not_active Abandoned
- 2013-04-30 CN CN201380029115.7A patent/CN104540945A/en active Pending
- 2013-04-30 KR KR20147033632A patent/KR20150004416A/en not_active Ceased
- 2013-04-30 CA CA2907616A patent/CA2907616A1/en not_active Abandoned
- 2013-04-30 EP EP13784572.3A patent/EP2844756A4/en not_active Ceased
- 2013-04-30 WO PCT/US2013/038840 patent/WO2013166000A1/en active Application Filing
- 2013-04-30 JP JP2015510379A patent/JP2015516989A/en active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110262485A1 (en) *	2008-08-04	2011-10-27	University Of Miami	Sting (stimulator of interferon genes), a regulator of innate immune responses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABE TAKAYUKI ET AL: "STING Recognition of Cytoplasmic DNA Instigates Cellular Defense", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 50, no. 1, 7 March 2013 (2013-03-07), pages 5 - 15, XP028547914, ISSN: 1097-2765, DOI: 10.1016/J.MOLCEL.2013.01.039 *
MARCO PRINZ ET AL: "Type I Interferons as Ambiguous Modulators of Chronic Inflammation in the Central Nervous System", FRONTIERS IN IMMUNOLOGY, vol. 3, 1 January 2012 (2012-01-01), XP055211634, DOI: 10.3389/fimmu.2012.00067 *
SCHULTZ J ET AL: "UPDATE ON ANTIVIRAL DNA VACCINE RESEARCH (1998-2000)", INTERVIROL, KARGER, CH, vol. 43, no. 4-06, 1 January 2000 (2000-01-01), pages 197 - 217, XP009055445, ISSN: 0300-5526, DOI: 10.1159/000053988 *
See also references of WO2013166000A1 *

Also Published As

Publication number	Publication date
CA2907616A1 (en)	2013-11-07
WO2013166000A1 (en)	2013-11-07
JP2015516989A (en)	2015-06-18
CN104540945A (en)	2015-04-22
AU2013256468A1 (en)	2014-12-04
EP2844756A1 (en)	2015-03-11
KR20150004416A (en)	2015-01-12

Publication	Publication Date	Title
EP2844756A4 (en)	2016-02-24	MODULATION OF IMMUNE RESPONSES
EP2879709A4 (en)	2016-03-23	MODULATION OF THE IMMUNE RESPONSE
EP2763896A4 (en)	2015-03-11	POLYROTOR TELEGUIDE
EP2900673A4 (en)	2016-10-19	MODULATION OF IRE1
CO6801776A2 (en)	2013-11-29	Cosmetic
EP2898326A4 (en)	2016-06-08	EFFECTIVE MODULATED IMAGING
EP2817275A4 (en)	2015-10-14	CONVERSION OF LIPIDS
EP2881022A4 (en)	2016-04-27	USTENSILE COOKING
DK3461895T3 (en)	2020-07-20	MODULATION OF UBE3A-ATS EXPRESSION
AR092198A1 (en)	2015-04-08	DERIVATIVES OF PIRAZOLOPIRIMIDINAS
EP2873453A4 (en)	2016-03-23	STIRRER
FR2998638B1 (en)	2016-04-15	CONNECTION
EP2888965A4 (en)	2016-05-11	KIMONO
ES2439418B1 (en)	2015-03-12	Cooking Field Device
EP2765913A4 (en)	2015-04-29	LANCET
EP2920756A4 (en)	2016-07-27	KNOWLEDGE OF CUSTOMERS
EP2915535A4 (en)	2016-08-24	INDUCER OF IMMUNE TOLERANCE
DE112013006030A5 (en)	2015-08-27	clutch
EP2916362A4 (en)	2016-06-22	Photodiode
HUE049492T2 (en)	2020-09-28	Modulation of privacy
ES2439417B1 (en)	2015-03-12	Cooking Field Device
EP2873417A4 (en)	2016-03-09	INDUCER OF IMMUNE TOLERANCE
FR2994309B1 (en)	2014-08-29	SIMULATION OF INSULAR KARSTIFICATION
DE112013005253A5 (en)	2015-10-08	Food Hacker
PT2820042T (en)	2019-10-31	IGG-STIMULATED REMYELINIZATION OF PERIPHERAL NERVES

Legal Events

Date	Code	Title	Description
2015-02-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2015-03-11	17P	Request for examination filed	Effective date: 20141201
2015-03-11	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2015-03-11	AX	Request for extension of the european patent	Extension state: BA ME
2015-10-21	RIC1	Information provided on ipc code assigned before grant	Ipc: C12N 15/11 20060101AFI20150914BHEP Ipc: A61K 31/711 20060101ALI20150914BHEP Ipc: A61P 35/00 20060101ALI20150914BHEP Ipc: A61K 31/713 20060101ALI20150914BHEP
2016-02-24	RA4	Supplementary search report drawn up and despatched (corrected)	Effective date: 20160126
2016-02-24	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/00 20060101ALI20160120BHEP Ipc: A61K 31/711 20060101ALI20160120BHEP Ipc: C12N 15/11 20060101AFI20160120BHEP Ipc: A61K 31/713 20060101ALI20160120BHEP
2017-01-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2017-03-01	17Q	First examination report despatched	Effective date: 20170131
2018-06-25	REG	Reference to a national code	Ref country code: DE Ref legal event code: R003
2018-07-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED
2018-11-21	18R	Application refused	Effective date: 20180625